文献速递中医内科中药与中成药合理使用

解郁安神汤单用或联用西药治疗精神障碍的系统评价与Meta分析

The effectiveness and safety of Chinese herbal Jieyu Anshen Decoction monotherapy or in combination with Western medicine for mental disorders: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Phytomedicine · 2025-10-06

该系统评价纳入95项RCT共8188例精神障碍患者,评估解郁安神汤单用或联用西药的有效性与安全性。结果显示联用帕罗西汀对抑郁和焦虑障碍疗效优于单用西药,单用对睡眠障碍优于艾司唑仑,且不良事件显著少于单用西药。

要点

  • 解郁安神汤联用帕罗西汀改善抑郁与焦虑疗效优于单用西药。
  • 单用解郁安神汤对睡眠障碍疗效优于艾司唑仑。
  • 解郁安神汤单用或联用西药的不良事件显著少于单用西药。

核心结论

  • 解郁安神汤单用或作为辅助治疗对精神障碍显示有前景的疗效和较好的安全性。

研究设计与样本

  • 比较解郁安神汤与23种西药,覆盖四类精神障碍。

主要发现

  • 辅助治疗中,联用帕罗西汀治疗抑郁障碍的有效率RR=1.18(95%CI:1.13-1.23),焦虑障碍RR=1.30(95%CI:1.17-1.44)。
  • 联用阿立哌唑治疗精神分裂症的有效率RR=1.21(95%CI:1.11-1.31)。
  • 单用治疗抑郁障碍,疗效与帕罗西汀相当且优于氟西汀;治疗睡眠障碍优于艾司唑仑(RR=1.15,95%CI:1.07-1.23)。
  • 联用帕罗西汀的不良事件显著少于单用西药(RR=0.13,95%CI:0.05-0.33)。

关键数值与推荐

  • 抑郁障碍联用帕罗西汀有效率RR=1.18(95%CI:1.13-1.23)。
  • 焦虑障碍联用帕罗西汀有效率RR=1.30(95%CI:1.17-1.44)。
  • 精神分裂症联用阿立哌唑有效率RR=1.21(95%CI:1.11-1.31)。
  • 睡眠障碍单用解郁安神汤有效率RR=1.15(95%CI:1.07-1.23)。
  • 联用帕罗西汀不良事件RR=0.13(95%CI:0.05-0.33)。

临床怎么用

  • 抑郁或焦虑障碍可考虑解郁安神汤联合帕罗西汀以提高疗效并减少不良事件。
  • 精神分裂症可考虑解郁安神汤联合阿立哌唑辅助治疗。
  • 睡眠障碍可考虑单用解郁安神汤作为艾司唑仑的替代选择。

局限性

  • 纳入研究的偏倚风险和证据质量已被评估,但原文摘要未报告具体分级结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mental disorders are a major global health challenge. While Western medicine (WM) is the primary treatment, its limitations create a need for complementary and alternative therapies. OBJECTIVE: Evaluate the effectiveness and safety of Chinese herbal medicine Jieyu Anshen Decoction (JYASD) in treating mental disorders, both as monotherapy and in combination with WM. METHODS: Eight databases were searched from their inception to October 2024. Randomized controlled trials (RCTs) on JYASD for mental disorders were included. Meta-analysis was performed, and Risk of bias and evidence quality were assessed. RESULTS: A total of 95 RCTs involving 8188 participants were included, comparing JYASD with 23 types of WM across four categories of mental disorders. For adjuvant therapy, JYASD combined with paroxetine showed superior effectiveness in treating depressive disorder (RR = 1.18, 95 % CI: 1.13-1.23) and anxiety disorders (RR = 1.30, 95 % CI: 1.17-1.44), with significant improvements in HAMD and HAMA scores compared with WM monotherapy. For schizophrenia, JYASD combined with aripiprazole showed positive effects compared with WM monotherapy (RR = 1.21, 95 % CI: 1.11-1.31). For monotherapy, JYASD was as effective as paroxetine and more than fluoxetine for depressive disorder, while showing significant advantage over estazolam for sleep disorders (RR = 1.15, 95 % CI: 1.07-1.23). Both adjuvant therapy and JYASD alone had significantly fewer adverse events than WM alone, especially with paroxetine (RR = 0.13, 95 % CI: 0.05-0.33). CONCLUSION: JYASD shows promising therapeutic value in treating mental disorders, both as monotherapy and adjuvant therapy, with favorable safety profiles and stable therapeutic effects.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Liu K, Shi ZY, Song YK, et al. The effectiveness and safety of Chinese herbal Jieyu Anshen Decoction monotherapy or in combination with Western medicine for mental disorders: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2025. PMID: 41056862. doi:10.1016/j.phymed.2025.157351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。